TSE:OGI Organigram (OGI) Stock Price, News & Analysis C$2.38 +0.07 (+3.03%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock About Organigram Stock (TSE:OGI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organigram alerts:Sign Up Key Stats Today's RangeC$2.27▼C$2.4250-Day RangeC$1.76▼C$2.3852-Week RangeC$1.22▼C$2.72Volume299,689 shsAverage Volume174,529 shsMarket CapitalizationC$294.03 millionP/E RatioN/ADividend YieldN/APrice TargetC$3.33Consensus RatingBuy Company Overview Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships. Read More Organigram Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreOGI MarketRank™: Organigram scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOrganigram has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOrganigram has received no research coverage in the past 90 days.Read more about Organigram's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Organigram is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organigram is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioOrganigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioOrganigram has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OGI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrganigram does not currently pay a dividend.Dividend GrowthOrganigram does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OGI. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for OGI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organigram insiders have not sold or bought any company stock.Percentage Held by Insiders31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.37% of the stock of Organigram is held by institutions.Read more about Organigram's insider trading history. Receive OGI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organigram and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGI Stock News HeadlinesOrganigram: The Capital Efficient Market Leader Trading At A DiscountAugust 18, 2025 | seekingalpha.comAtb Cap Markets Reduces Earnings Estimates for OrganigramAugust 18, 2025 | americanbankingnews.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 28 at 2:00 AM | Timothy Sykes (Ad)Analysts Offer Insights on Healthcare Companies: OrganiGram Holdings (OGI) and Dogwood Therapeutics (DWTX)August 16, 2025 | theglobeandmail.comOrganigram Global Inc. (NASDAQ:OGI) Q3 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comOrganigram Holdings Q3 2025 Earnings PreviewAugust 13, 2025 | msn.comOrganigram Global scales US presence, expands hemp-derived THC beverage portfolio - Seeking AlphaJuly 9, 2025 | seekingalpha.comOrganigram Global scales US presence, expands hemp-derived THC beverage portfolioJuly 8, 2025 | msn.comSee More Headlines OGI Stock Analysis - Frequently Asked Questions How have OGI shares performed this year? Organigram's stock was trading at C$2.30 on January 1st, 2025. Since then, OGI shares have increased by 3.5% and is now trading at C$2.38. How do I buy shares of Organigram? Shares of OGI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Organigram own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Innovative Industrial Properties (IIPR), Aurora Cannabis (ACB), Canopy Growth (WEED), Aphria (APHA) and NVIDIA (NVDA). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryCannabis Current SymbolTSE:OGI CIKN/A Webwww.organigram.ca Phone844-644-4726FaxN/AEmployees987Year FoundedN/APrice Target and Rating Average Price Target for OrganigramC$3.33 High Price TargetC$3.50 Low Price TargetC$3.15 Potential Upside/Downside+39.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)C($0.47) Trailing P/E RatioN/A Forward P/E Ratio14.58 P/E Growth0.42Net Income-C$57.23 million Net Margins-31.69% Pretax MarginN/A Return on Equity-17.59% Return on Assets-5.56% Debt Debt-to-Equity Ratio3.07 Current Ratio3.36 Quick Ratio2.62 Sales & Book Value Annual SalesC$180.58 million Price / Sales1.63 Cash FlowC$0.62 per share Price / Cash Flow3.85 Book ValueC$2.85 per share Price / Book0.84Miscellaneous Outstanding Shares123,542,347Free FloatN/AMarket CapC$294.03 million OptionableNot Optionable Beta1.13 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (TSE:OGI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.